AVNS Stock Records Historic Intraday Surge – Everything To Know About The Buyout Deal By American Industrial Partners

• Under the agreement, Avanos shareholders will receive $25 per share in cash.
• After the completion of the deal, Avanos will become a private company and will no longer be listed on the New York Stock Exchange.
• The company had a debt of $100.5 million at the end of the fourth quarter of fiscal 2025.

Shares of Avanos Medical, Inc. (AVNS) surged 70% to record their biggest ever intraday gains after the medical technology firm agreed to be taken private in an all-cash acquisition by affiliates of American Industrial Partners.

AVNS shares jumped to their highest since September 2024.

Avanos and American Industrial Partners (AIP) have agreed to an all-cash acquisition deal valued at about $1.27 billion. Under the agreement, Avanos shareholders will receive $25 per share in cash, representing a premium of about 72% to the stock’s last closing price and nearly 83% above its 30-day average.

When Is The Deal Expected To Close?

The deal has been approved by the company’s board and is expected to close in the second half of 2026. After completion, Avanos will become a private company and will no longer be listed on the New York Stock Exchange.

“Partnering with AIP will better enable us to build on our progress, advance our innovation roadmap, and strengthen our competitive position with enhanced flexibility and resources,” said David Pacitti, Avanos’ CEO.

Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.

Balance Sheet Overview

According to the company’s fourth-quarter (Q4) results, its cash balance was $89.8 million at the end of 2025, down from $107.7 million at year-end 2024. Total debt at the end of Q4 was $100.5 million.

The company expects full-year 2026 net sales of $700 million to $720 million, roughly in line with $701.2 million reported in 2025. It also forecasts earnings of $0.90 to $1.10 per share, compared with a net loss of $72.9 million in the prior year.

Avanos makes medical devices for non-opioid pain treatment and nutrition, including feeding tubes for patients who cannot eat on their own. Its key product, Coolief, uses a minimally invasive technology to treat chronic pain by targeting nerves without using opioids.

Year-to-date, the stock has gained more than 116%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.